[What are the indications for proton pump inhibitors? R. Arnold, Marburg, elaborates on the clinical aspects of the controversy regarding lansoprazole. Interview by Gerrit Lichtenberg].
Arnold
R
R
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000818:Animals; D000897:Anti-Ulcer Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015197:Carcinogenicity Tests; D002276:Carcinoid Tumor / Q000139:chemically induced*; D004942:Esophagitis, Peptic / Q000188:drug therapy; D016481:Helicobacter Infections / Q000188:drug therapy; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy; D051381:Rats; D013274:Stomach Neoplasms / Q000139:chemically induced*; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D009853:Omeprazole
Welche Indikationen für Protonenpumpen-Hemmer? R. Arnold, Marburg, äussert sich zum fachlichen Teil des Streites um Lansoprazol.